

# JosÃ© Luis Zamorano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2627654/publications.pdf>

Version: 2024-02-01

110  
papers

4,928  
citations

87723

38  
h-index

98622

67  
g-index

113  
all docs

113  
docs citations

113  
times ranked

7260  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multimodality Imaging of Diseases of the Thoracic Aorta in Adults: From the American Society of Echocardiography and the European Association of Cardiovascular Imaging. <i>Journal of the American Society of Echocardiography</i> , 2015, 28, 119-182.	1.2	500
2	Echocardiographic reference ranges for normal cardiac chamber size: results from the NORRE study. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 680-690.	0.5	324
3	Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2020, 22, 1504-1524.	2.9	234
4	Echocardiographic reference ranges for normal left ventricular 2D strain: results from the EACVI NORRE study. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 833-840.	0.5	228
5	Echocardiographic reference ranges for normal non-invasive myocardial work indices: results from the EACVI NORRE study. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 582-590.	0.5	204
6	Echocardiographic reference ranges for normal cardiac Doppler data: results from the NORRE Study. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 16, 1031-41.	0.5	184
7	Admission of patients with STEMI since the outbreak of the COVID-19 pandemic: a survey by the European Society of Cardiology. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2020, 6, 210-216.	1.8	181
8	2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. <i>European Heart Journal</i> , 2018, 39, 1131-1143.	1.0	171
9	Echocardiographic reference ranges for normal left atrial function parameters: results from the EACVI NORRE study. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 630-638.	0.5	159
10	European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. <i>European Heart Journal</i> , 2017, 38, ehw480.	1.0	137
11	Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1169-1178.	1.2	133
12	Open issues in transcatheter aortic valve implantation. Part 2: procedural issues and outcomes after transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2014, 35, 2639-2654.	1.0	105
13	SOURCE 3: 1-year outcomes post-transcatheter aortic valve implantation using the latest generation of the balloon-expandable transcatheter heart valve. <i>European Heart Journal</i> , 2017, 38, 2717-2726.	1.0	105
14	Open issues in transcatheter aortic valve implantation. Part 1: patient selection and treatment strategy for transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2014, 35, 2627-2638.	1.0	96
15	Three-dimensional echocardiographic quantification of the left-heart chambers using an automated adaptive analytics algorithm: multicentre validation study. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 47-58.	0.5	91
16	Standards defining a "Heart Valve Centre™": ESC Working Group on Valvular Heart Disease and European Association for Cardiothoracic Surgery Viewpoint. <i>European Heart Journal</i> , 2017, 38, 2177-2183.	1.0	83
17	Two-dimensional transthoracic echocardiographic normal reference ranges for proximal aorta dimensions: results from the EACVI NORRE study. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 167-179.	0.5	81
18	The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. <i>European Heart Journal</i> , 2021, 42, 1254-1269.	1.0	78

#	ARTICLE	IF	CITATIONS
19	3D echocardiographic reference ranges for normal left ventricular volumes and strain: results from the EACVI NORRE study. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 475-483.	0.5	74
20	Innovative imaging methods in heart failure: a shifting paradigm in cardiac assessment. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 1615-1633.	2.9	74
21	Imaging to select and guide transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2014, 35, 1578-1587.	1.0	71
22	Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. <i>European Heart Journal Supplements</i> , 2016, 18, C2-C12.	0.0	71
23	Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 69, 409-419.	1.2	67
24	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. <i>Atherosclerosis Supplements</i> , 2015, 19, 1-12.	1.2	66
25	Correlation between non-invasive myocardial work indices and main parameters of systolic and diastolic function: results from the EACVI NORRE study. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 533-541.	0.5	63
26	The cancer patient and cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 2290-2309.	2.9	62
27	Prognostic implications of global myocardial mechanics in hypertrophic cardiomyopathy by cardiovascular magnetic resonance feature tracking. Relations to left ventricular hypertrophy and fibrosis. <i>International Journal of Cardiology</i> , 2017, 249, 467-472.	0.8	55
28	Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. <i>European Heart Journal</i> , 2020, 41, 347-356.	1.0	55
29	New oral anticoagulants: a practical guide for physicians. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 134-145.	1.4	54
30	Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 474-486.	0.4	54
31	6-Month Outcomes of the TricValve System in Patients With Tricuspid Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 1366-1377.	1.1	51
32	Multimodality imaging evaluation of Chagas disease: an expert consensus of Brazilian Cardiovascular Imaging Department (DIC) and the European Association of Cardiovascular Imaging (EACVI). <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 459-460n.	0.5	48
33	Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 181-195.	2.9	47
34	Updated standards and processes for accreditation of echocardiographic laboratories from The European Association of Cardiovascular Imaging. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 717-727.	0.5	46
35	Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: subanalysis of ODYSSEY COMBO II. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 989-996.	2.2	46
36	Prognostic value of left atrial function by cardiovascular magnetic resonance feature tracking in hypertrophic cardiomyopathy. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 1055-1065.	0.7	43

#	ARTICLE	IF	CITATIONS
37	Overview of mitral regurgitation in Europe: results from the European Registry of mitral regurgitation (EuMiClip). <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 503-507.	0.5	42
38	Frailty is an independent prognostic marker in elderly patients with myocardial infarction. <i>Clinical Cardiology</i> , 2017, 40, 925-931.	0.7	41
39	Myocardial injury determination improves risk stratification and predicts mortality in COVID-19 patients. <i>Cardiology Journal</i> , 2020, 27, 489-496.	0.5	39
40	Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 611-621.	0.8	33
41	The Role of Frailty in Acute Coronary Syndromes in the Elderly. <i>Gerontology</i> , 2018, 64, 422-429.	1.4	32
42	Characteristics and outcomes of atrial fibrillation patients with or without specific symptoms: results from the PREFER in AF registry. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2016, 2, 299-305.	1.8	31
43	Predictors of persistent pulmonary hypertension after mitral valve replacement. <i>Heart and Vessels</i> , 2016, 31, 1091-1099.	0.5	31
44	Echocardiographic reference ranges for normal left ventricular layer-specific strain: results from the EACVI NORRE study. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 896-905.	0.5	29
45	Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. <i>Heart</i> , 2014, 100, 1625-1635.	1.2	27
46	SARS-CoV-2, a novel virus with an unusual cardiac feature: inverted takotsubo syndrome. <i>European Heart Journal</i> , 2020, 41, 3106-3106.	1.0	26
47	Cardiac imaging in prosthetic paravalvular leaks. <i>Cardiovascular Diagnosis and Therapy</i> , 2014, 4, 307-13.	0.7	23
48	Accuracy and reproducibility of novel echocardiographic three-dimensional automated software for the assessment of the aortic root in candidates for transcatheter aortic valve replacement. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 772-778.	0.5	22
49	Large-scale assessment of aortic stenosis: facing the next cardiac epidemic?. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 1142-1148.	0.5	22
50	Reproducibility of a novel echocardiographic 3D automated software for the assessment of mitral valve anatomy. <i>Cardiovascular Ultrasound</i> , 2015, 14, 17.	0.5	21
51	Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 74-84.	0.7	21
52	Rationale and design of the EACVI AFib Echo Europe Registry for assessing relationships of echocardiographic parameters with clinical thrombo-embolic and bleeding risk profile in non-valvular atrial fibrillation. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 245-252.	0.5	16
53	Risk factors for in-hospital mortality in patients with acute myocardial infarction during the COVID-19 outbreak. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 985-993.	0.4	16
54	Quality Markers in Cardiology. Main Markers to Measure Quality of Results (Outcomes) and Quality Measures Related to Better Results in Clinical Practice (Performance Metrics). <i>INCARDIO (Indicadores)</i> <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 976-995.e10.	0.4	15

#	ARTICLE	IF	CITATIONS
55	Eficiencia de la combinaciÃ³n naproxeno/esomeprazol para el tratamiento de la artrosis en EspaÃ±a. ReumatologÃ­a ClÃ­nica, 2014, 10, 210-217.	0.2	14
56	Cost-effectiveness Analysis Comparing Apixaban and Acenocoumarol in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation in Spain. Revista Espanola De Cardiologia (English Ed ), 2015, 68, 680-690.	0.4	14
57	Echocardiographic guidance in transcatheter structural cardiac interventions. EuroIntervention, 2022, 17, 1205-1226.	1.4	14
58	Intravenous ivabradine for control of heart rate during coronary CT angiography: A randomized, double-blind, placebo-controlled trial. Journal of Cardiovascular Computed Tomography, 2015, 9, 286-294.	0.7	13
59	Standards defining a â€œHeart Valve Centreâ€™: ESC Working Group on Valvular Heart Disease and European Association for Cardiothoracic Surgery Viewpoint. European Journal of Cardio-thoracic Surgery, 2017, 52, 418-424.	0.6	13
60	New prospects for PCSK9 inhibition?. European Heart Journal, 2018, 39, 2600-2601.	1.0	13
61	Geometrical and functional cardiac changes after cardiac surgery: a fisiopatological explanation based on speckle tracking. International Journal of Cardiovascular Imaging, 2018, 34, 1905-1915.	0.7	13
62	Updated standards and processes for accreditation of echocardiographic laboratories from The European Association of Cardiovascular Imaging: an executive summary. European Heart Journal Cardiovascular Imaging, 2014, 15, 1188-1193.	0.5	12
63	<sc>ESC</sc> suddenâ€­death risk model in hypertrophic cardiomyopathy: Incremental value of quantitative contrastâ€­enhanced <sc>CMR</sc> in intermediateâ€­risk patients. Clinical Cardiology, 2017, 40, 853-860.	0.7	11
64	Contact force-sensing catheters: performance in an ex vivo porcine heart model. Journal of Interventional Cardiac Electrophysiology, 2018, 53, 141-150.	0.6	11
65	â€œCardiotoxicityâ€™: time to define new targets?. European Heart Journal, 2020, 41, 1730-1732.	1.0	10
66	Right ventricle assessment in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. Echocardiography, 2020, 37, 586-591.	0.3	9
67	Prognostic implications of cardiac magnetic resonance feature tracking derived multidirectional strain in patients with chronic aortic regurgitation. European Radiology, 2021, 31, 5106-5115.	2.3	9
68	Severe aortic stenosis patients with preserved ejection fraction according to flow and gradient classification: Prevalence and outcomes. International Journal of Cardiology, 2017, 248, 211-215.	0.8	8
69	Global longitudinal strain is a hallmark of cardiac damage in mitral regurgitation: the Italian arm of the European Registry of mitral regurgitation (EuMiClip). Cardiovascular Ultrasound, 2019, 17, 28.	0.5	8
70	Impact of right ventricular systolic function in patients with significant tricuspid regurgitation. A cardiac magnetic resonance study. International Journal of Cardiology, 2021, 339, 120-127.	0.8	7
71	Would the Use of Edoxaban Be Cost-effective for the Prevention of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation in Spain?. Revista Espanola De Cardiologia (English Ed ), 2019, 72, 398-406.	0.4	6
72	Effect of diastolic dysfunction on intraventricular velocity behavior in early diastole by flow mapping. International Journal of Cardiovascular Imaging, 2019, 35, 1627-1636.	0.7	6

#	ARTICLE	IF	CITATIONS
73	Initial Experience With the DirectFlow Percutaneous Aortic Valve in Spain. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2014, 67, 954-956.	0.4	5
74	Sacubitril/valsartan and Bâ€type natriuretic peptide value: recalculating route. <i>European Journal of Heart Failure</i> , 2020, 22, 162-163.	2.9	5
75	The year in cardiovascular medicine 2020: imaging. <i>European Heart Journal</i> , 2021, 42, 740-749.	1.0	5
76	A rare cause of tough coronary occlusion. <i>European Heart Journal</i> , 2016, 37, ehv601.	1.0	4
77	Energy Dissipation in Resynchronization Therapy: Impact of Atrioventricular Delay. <i>Journal of the American Society of Echocardiography</i> , 2019, 32, 744-754.e1.	1.2	4
78	Feasibility and Reproducibility of Left Atrium Measurements Using Different Three-Dimensional Echocardiographic Modalities. <i>Diagnostics</i> , 2020, 10, 1043.	1.3	4
79	Theranostic Contribution of Extracellular Matrix Metalloprotease Inducer-Paramagnetic Nanoparticles Against Acute Myocardial Infarction in a Pig Model of Coronary Ischemia-Reperfusion. <i>Circulation: Cardiovascular Imaging</i> , 2022, 15, .	1.3	4
80	Mitral-Aortic Flow Reversal in Cardiac Resynchronization Therapy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, e004927.	2.1	3
81	Nanotechnology Applied to Preserve Extracellular Matrix as Teranostic Tool in Acute Myocardial Infarction. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2019, 72, 171-174.	0.4	3
82	Ivabradine induces cardiac protection by preventing cardiogenic shock-induced extracellular matrix degradation. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2021, 74, 1062-1071.	0.4	3
83	High-density mapping with fragmentation analysis in patients with reentrant atrial tachycardias (MAP-FLURHY study). <i>Journal of Interventional Cardiac Electrophysiology</i> , 2021, , 1.	0.6	3
84	Current perspectives on the use of statins in the treatment of dyslipidaemic patients: focus on pitavastatin. <i>Drugs in Context</i> , 2020, 9, 1-11.	1.0	3
85	A 3-Biomarker 2-Point-Based Risk Stratification Strategy in Acute Heart Failure. <i>Frontiers in Physiology</i> , 2021, 12, 708890.	1.3	3
86	Left ventricular ejection fractionâ€  What else?. <i>Cardiology Journal</i> , 2020, 27, 6-7.	0.5	3
87	Prognostic value of diastolic function parameters in significant aortic regurgitation: the role of the left atrial strain. <i>Journal of Echocardiography</i> , 2022, 20, 216-223.	0.4	3
88	Clinical Implications from Three-dimensional Echocardiographic Analysis in Hypertrophic Cardiomyopathy. <i>Current Cardiovascular Imaging Reports</i> , 2014, 7, 1.	0.4	2
89	Imaging in HF-PEF with Cardiovascular Magnetic Resonance. <i>Current Cardiovascular Imaging Reports</i> , 2015, 8, 1.	0.4	2
90	It paces right but not in the right space!. <i>European Heart Journal</i> , 2016, 37, 496-496.	1.0	2

#	ARTICLE	IF	CITATIONS
91	Effects of Ivabradine on Heart Rate and Hemodynamic Parameters in a Swine Model of Cardiogenic Shock. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 1139-1141.	0.4	2
92	Metformin in the era of new antidiabetics. <i>Future Cardiology</i> , 2021, 17, 475-485.	0.5	2
93	Stabilization of unstable reentrant atrial tachycardias via fractionated continuous electrical activity ablation (CHAOS study). <i>Cardiology Journal</i> , 2023, 30, 799-809.	0.5	2
94	Perforated Aortic Valve Aneurysm Due to Infective Endocarditis. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 222.	0.4	1
95	Chronic giant hydatid cyst fistulized to the left ventricle: long-term survival without surgery. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 16, 798-798.	0.5	1
96	Vector Flow Mapping in Mitral Valve Disease: a Novel Method for the Assessment of Flow Mechanics and Their Potential Implications for Mitral Valve Repair. <i>Current Cardiovascular Imaging Reports</i> , 2015, 8, 1.	0.4	1
97	Prevalence of optimal valve morphology for MitraClip in patients with mitral regurgitation. <i>Echocardiography</i> , 2017, 34, 1122-1129.	0.3	1
98	Ageing-related ILK levels are associated with calcified aortic valve and circulating miR 199-3p levels. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 75, 88-88.	0.4	1
99	Coronary compression caused by extrinsic adventitial damage: case of an early complication of trans-catheter tricuspid annuloplasty with cardioband device. <i>European Heart Journal</i> , 2021, 42, 3886-3886.	1.0	1
100	Hipertensi3n pulmonar tromboemb3lica cr3nica: la experiencia mejora los resultados. <i>Archivos De Bronconeumologia</i> , 2014, 50, 507-508.	0.4	0
101	Significant transaortic gradient after direct flow aortic valve implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 347-352.	0.7	0
102	Atypical Response to Diagnostic Maneuvers in a Narrow QRS Tachycardia: What is the Mechanism?. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2015, 38, 1481-1484.	0.5	0
103	Heart failure in a patient with a pacemaker. <i>Heart</i> , 2015, 101, 484-484.	1.2	0
104	Aortitis With Associated Left Main Coronary Artery Stenosis: Role of Cardiac Computed Tomography. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1574.e5-1574.e7.	0.8	0
105	Usefulness of Reciprocal Changes in the Diagnosis of Myocardial Infarction With Minimal ST-segment Elevation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 706-707.	0.4	0
106	RE: Use of anticoagulation in patients with breast cancer and atrial fibrillation. <i>Breast</i> , 2019, 48, 99.	0.9	0
107	Lessons from follow-up after percutaneous mitral valve repair: "you are judged by the company you keep". <i>European Journal of Heart Failure</i> , 2019, 21, 1632-1634.	2.9	0
108	Cardio-oncology: the questions to be solved. <i>Kardiologia Polska</i> , 2021, 79, 112-113.	0.3	0

#	ARTICLE	IF	CITATIONS
109	The use of Bayes factor in clinical cardiology research. Response. Revista Espanola De Cardiologia (English Ed ), 2021, 74, 642-643.	0.4	0
110	Simultaneous percutaneous repair in mitral and tricuspid regurgitation: step by step. Revista Espanola De Cardiologia (English Ed ), 2020, 73, 1085-1086.	0.4	0